HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: CJN.01220308v1 3/5/1542    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, J. J. Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Hsu, J. J. Articles by Demer, L. L.

Vitamin D and Osteogenic Differentiation in the Artery Wall

Jeffrey J. Hsu^*, Yin Tintut^*, and Linda L. Demer^*,

Departments of ^* Medicine and Physiology/Biomedical Engineering, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California

Correspondence: Dr. Linda L. Demer, Departments of Medicine, Physiology, and Biomedical Engineering, Box 951679, UCLA, Los Angeles, CA 90095-1679. Phone: 310-206-2677; Fax: 310-825-4963; E-mail: ldemer{at}mednet.ucla.edu

	Abstract

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
Vascular calcification is widespread, particularly in patients with chronic kidney disease, who receive, among other treatments, active vitamin D supplements. Emerging evidence indicates that vascular calcification is a regulated process that resembles embryonic endochondral osteogenesis, involving osteoblastic differentiation of vascular smooth muscle cells. In experimental animal models, high dosages of vitamin D consistently promote vascular calcification. In particular, the vitamin D–fed rat is frequently used as a model to assess putative regulators of calcific vasculopathy. The artery wall calcification in these animals most likely results from multiple mechanisms involving systems physiology of the complex, bone-vascular-renal-endocrine axis. Genetically engineered mice with upregulated vitamin D signaling pathways have also shed light on the molecular intermediaries, including fibroblast growth factor-23 and transcriptional intermediary factor 1-. In contrast to the studies of animals, studies of humans show that vitamin D has an inverse relationship or little effect. This difference between in vitro and in vivo findings is most likely, again, due to the complex, systemic feedback regulatory mechanisms that control calcium-phosphate metabolism. Recent epidemiologic evidence suggests that there is a narrow range of vitamin D levels in which vascular function is optimized. Levels above or below this range seem to confer a significant increase in risk for cardiovascular disease. There is some evidence to suggest that dietary vitamin D may be carried by lipoprotein particles into cells of the artery wall and atherosclerotic plaque, where it may be converted to active form by monocyte-macrophages. These findings raise interesting questions regarding the effects of vitamin D intake on atherosclerotic calcification and cardiovascular risk.

	Introduction

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
Cardiovascular disease is the leading cause of death among adults with chronic kidney disease (1), with 10- to 20-fold higher mortality rate (2). It seems that a key contributor to the cardiovascular complications seen in these patients is vascular calcification (calcific arteriolopathy), a pathological process that is widely known to increase the risk for cardiac and vascular events (e.g., myocardial infarction, stroke) (3–5). Vascular calcification is particularly prevalent in patients with chronic kidney disease (CKD), (6) even among pediatric patients (7). Growing evidence indicates that multiple factors contribute to vascular calcification in CKD (8). Hyperphosphatemia is a common clinical finding in patients with CKD, and Wada et al. (9) showed that increased serum levels of inorganic phosphate induce matrix mineralization in smooth muscle cells in vitro. In addition, calcitriol has been used widely in patients with CKD to prevent development of secondary hyperparathyroidism as a result of the impaired ability of the diseased kidney to convert vitamin D into its active form, 1,25(OH)₂D₃. Calcitriol increases serum calcium levels and suppresses parathyroid hormone (PTH) release; although this treatment addresses the secondary hyperparathyroidism, the resulting increase in serum calcium levels, together with increased serum phosphate (10), may have the adverse effect of promoting mineralization in the vasculature. The greater prevalence of vascular calcification in patients with CKD and the increased use of vitamin D metabolites in the treatment of these patients together beg the question of whether vitamin D intake contributes to vascular calcification. An in-depth review on this question has been provided by Norman and Powell (11).

The cellular and molecular mechanisms of vascular and cardiac valvular calcification have been studied in great detail (see reviews by Shao et al. [12] and Abedin et al. [13]). In seminal studies, Towler and colleagues (14) demonstrated a key role of molecular Wnt signaling cascades in osteoblastic differentiation of vascular cells. Calcium deposits may be found at many sites in the cardiovascular tree, including the medial layer of the large arteries (medial arterial calcification); within atherosclerotic plaque (intimal calcification); on cardiac valves (15), particularly mitral and aortic; and in the microvessels (calcific uremic arteriolopathy). Calcium deposition at these different sites follows different clinical courses, and they seem to have at least some distinct pathophysiologic features. In approximately 15% of human atherosclerotic plaque, the calcium deposits develop complete bone architecture, histologically indistinguishable from trabecular bone, even including marrow and cartilage (16). Transitional stages corresponding with the stages of embryonic endochondral ossification may be seen in human plaque (17). This seeming contrast between the clinical and laboratory views of the relationship of vitamin D to the osteogenic differentiation of vascular cells is the focus of this brief survey highlighting some of the current literature in this complex field.

	Cell and Organ Culture Studies

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
Vascular cell calcification has been shown to occur in vitro in bovine and human cells (18–20), following the same molecular events and a similar time course as seen in osteoblast differentiation in vitro (21). The in vitro model has been used extensively to identify a wide range of activators and inhibitors that control osteogenic differentiation of vascular cells (22). In both bovine and human vascular smooth muscle cell cultures, active vitamin D treatment induces osteoblastic differentiation as evidenced by induction of alkaline phosphatase activity, an established marker of osteogenesis in cultured cells, as well as its gene expression (23). This effect is mediated, at least in part, through increased secretion of PTH-related peptide (23). In human vascular smooth muscle cells, 1,25(OH)₂D₃ has been shown to induce matrix calcium incorporation in the presence of TNF-, oncostatin M, and IFN- (24). Cellular uptake of calcium is also induced by 1,25(OH)₂D₃ in rat aortic smooth muscle cells (25). In contrast, in organ culture of rat aortic segments in serum-free medium, calcitriol treatment did not promote calcium incorporation (26).

Other aspects of vascular function besides mineralization are also affected by vitamin D. Canfield and colleagues (27) showed that vitamin D inhibits vascular endothelial growth factor–induced endothelial cell sprouting, as well as the formation of endothelial cell networks within three-dimensional collagen gels. They further showed that 1,25(OH)₂D₃ promoted cellular regression as a result of apoptosis, specifically within the sprouting cell population, a phenomenon confirmed in vivo. Even artery wall contractility is affected by vitamin D, as shown in ex vivo arterial segments (28).

It is interesting that 1,25(OH)₂D₃ is carried by low density lipoprotein particles and internalized by cells via the LDL receptor (29); whereas vitamin D generated by ultraviolet exposure is primarily carried in the bloodstream on vitamin D binding protein. As a fat-soluble vitamin, dietary cholecalciferol may be carried into the bloodstream from the intestinal villi inside chylomicrons and transferred to LDL particles in the liver (30). Thus, LDL particles accumulating in artery walls to produce atherosclerotic plaque may bring vitamin D with them. Approximately 16% of 1,25(OH)₂D₃ and approximately 3% of 25(OH)D are carried in lipoprotein particles (29). Once in the subendothelial space or atherosclerotic plaque, 25(OH)D may be converted to active form by 1-hydroxylase expressed in the abundant monocyte-derived cells (31). Vitamin D is known to induce a variety of factors that contribute to atherogenesis or vascular calcification (e.g., type I collagen, vascular endothelial growth factor, matrix metalloproteinases, elastin) and to induce apoptosis, which may promote vascular calcification in vitro (32). Thus, it is possible that dietary vitamin D may have a direct role in vascular pathology (see the comprehensive review by Norman and Powell [11]).

	Animal Models of Vascular Calcification

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
Hypervitaminosis D Induces Vascular Calcification
It has been known for decades that high-dosage vitamin D reliably produces vascular calcification in animal models. In the 1960s, vitamin D excess was shown to induce vascular calcification and thrombosis in rats. Hypervitaminosis D also produces atherosclerosis and vascular calcification in arteries of rabbits with moderate hyperlipidemia (33). Vitamin D was also shown to accelerate vascular calcification in Rhesus monkeys with experimental arteriosclerosis generated by nicotine and high dietary cholesterol (34). This in vivo effect of vitamin D on vascular calcification has been reproduced consistently in studies from several investigative groups using cholecalciferol and/or calcitriol in the rat model (35–38).

Rodent Models of Hypervitaminosis D
Price et al. (39) developed a rat model of vascular calcification using warfarin, which inhibits vitamin K–dependent -carboxylation of matrix GLA protein, a known inhibitor of vascular calcification in vivo (40,41). In this warfarin model, which, as expected, resembles the matrix GLA protein–deficient mouse phenotype, vascular calcification occurred much more rapidly with high-dosage cholecalciferol treatment (37). In rats with surgically induced renal insufficiency, vitamin D treatment leads to aortic calcification, with consequent hypertension, left ventricular hypertrophy, and aortic aneurysms (42).

Genetically Modified Mice
A link between vitamin D signaling and vascular calcification is suggested by the finding of vascular calcification in mice deficient in transcriptional intermediary factor 1- (TIF1), a tumor suppressor in hepatocytes. TIF1 represses the vitamin D receptor pathway, and, as a result, the TIF1-deficient mice have enhanced vitamin D receptor signaling, suggesting a link between increased vitamin D receptor signaling and calcific vasculopathy.

Another link was initially suggested by the finding of calcific arteriolopathy (medial calcification) in mice deficient in fibroblast growth factor-23, which negatively regulates 1-hydroxylase. These mice develop vascular calcification (43,44); however, fibroblast growth factor-23 also inhibits renal phosphate resorption in response to high phosphate levels, and it was subsequently shown that a low-phosphate diet reversed the phenotype, indicating that hyperphosphatemia accounted for the vascular calcification in this model (45).

Modifiers of Vitamin D–Induced Vascular Calcification
A ubiquitous serum protein, fetuin-A, also known as 2-Heremans-Schmid glycoprotein, is considered by some to be a systemic inhibitor of vascular calcification, and loss of serum fetuin has been observed with excess vitamin D (46,47). Thus, in some cases, vitamin D may promote calcification by reducing circulating levels of fetuin-A. Several investigative groups have shown that osteoprotegerin (OPG), a soluble decoy receptor in the TNF receptor family, inhibits vitamin D–induced calcification (35,47–49). The findings suggest that vitamin D may affect atherosclerotic calcification via effects on OPG or its target, the ligand for receptor activator of NF-B, a critical osteoclast differentiation factor. It is interesting that OPG also reduces hyperlipidemia-induced calcification, independent of vitamin D levels (50). Osteoclast-like cells have been found in the artery wall, and their resorptive activity is driven by carbonic anhydrase, which has a vitamin D response element in its gene promoter (51). One positive modifier of vitamin D–induced vascular calcification is magnesium deficiency. Low dietary magnesium has been shown to enhance coronary arterial calcification and ultrastructural changes of endothelial cells in vitamin D–fed swine (52).

	Clinical Studies of Vitamin D and Coronary and Aortic Calcification

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
Inverse Relationship between Endogenous Vitamin D Levels and Vascular Disease
In contrast to the findings in animals, many clinical studies show an inverse relationship between vitamin D levels and vascular calcification. Calcification of the coronary arteries, measured as a "calcium score" by electron beam computed tomography (EBCT), correlates inversely with 1,25(OH)₂D₃ in patients with familial hypercholesterolemia and coronary artery disease, as shown by Watson et al. (53). Consistent with this, Doherty et al. (54) showed an inverse relationship between EBCT calcium score and endogenous 1,25(OH)₂D₃ in patients with high scores on the Framingham coronary risk scale. This relationship was independent of racial/ethnic origin. More recently, London et al. examined patients with CKD for a relationship of serum vitamin D parameters with aortic calcification, on the basis of roentgenographic and echocardiographic images, as well as with aortic stiffness measured by pulse-wave velocity. Results showed no relationship with relatively weak measures of aortic calcification, yet a significant inverse relation between vascular stiffness and both 25(OH)D₃ and 1,25(OH)₂D₃ was seen (55). Because aortic stiffness often reflects calcification, one might expect that quantitative measures of aortic calcification, such as calibrated computed tomographic analysis, may reveal a relationship; however, in patients who underwent coronary angiography and calibrated EBCT scanning, serum concentrations of 1,25(OH)₂D₃ had no significant correlation with levels of coronary calcification (56). The more physiologically relevant comparison between quantitative aortic calcification and levels of 25(OH)D₂ remains to be determined.

Supplemental Vitamin D and Vascular Disease
It is notable that in animals, vitamin D treatment has a positive relationship with vascular calcification, whereas in humans, endogenous vitamin D levels have a negative relationship with coronary calcification. One consideration is that vitamin D may have a biphasic relation with risk, promoting vascular calcification in both excess and deficiency. If so, then treatment studies may reflect the effects of high vitamin D levels for which the relationship is positive, whereas observational studies of endogenous levels may reflect the lower range for which the relationship is inverse. Another consideration is that, although dietary intake of vitamin D may correlate with levels of 25(OH)D (57), serum levels of 1,25(OH)₂D₃, which is not considered a marker of hormonal status, may vary independently of dietary intake and inversely with 25(OH)D (58). Most clinical studies involve either no vitamin D supplementation or retrospective, nonrandomized vitamin D supplementation. Fewer studies involve prospective, randomized supplementation. In nonrandomized studies, calcitriol intake was not related to the presence of coronary artery calcification, although coronary calcification did correlate with higher serum phosphorous, calcium-phosphorus product (Ca x P), and daily intake of calcium in pediatric patients with CKD (6). In another study of pediatric patients with CKD, in which coronary calcification incidence was 15%, calcitriol intake was a minor contributor to coronary calcification in a multivariable regression model. The major predictors were serum phosphorus and cumulative exposure to calcium-containing oral phosphate-binding agents (7). In another observational treatment study of humans, vitamin D supplementation had a positive independent association with microvascular calcification (calcific uremic arteriolopathy) (59); however, in the National Institutes of Health Women's Health Initiative studies, investigators found no significant effect of calcium/vitamin D supplementation on cardiovascular disease in >36,000 healthy postmenopausal women (60). Recent evidence supports the existence of a biphasic relationship of serum 25(OH)D with cardiovascular disease. In the Framingham Offspring Study, involving >1700 participants without symptoms and previous cardiovascular disease and a mean follow-up of 5.4 yr, the relationship between serum vitamin D [25(OH)D] and cardiovascular disease was found to be biphasic with risk increasing at levels <15 and >30 ng/ml. Thus, both vitamin D deficiency and vitamin D excess increase the risk for cardiovascular disease. This relation could be mediated in part by secondary hyperparathyroidism (61).

Calcific Uremic Arteriolopathy
Calcific uremic arteriolopathy (CUA), formerly known as calciphylaxis, is a life-threatening form of medial arterial calcification that leads to necrotic skin lesions and gangrene. Microvessels and surrounding soft tissue may also mineralize, the latter of which occurs in a process referred to as calcinosis. This process leaves painful nodules and necrosis, sometimes gangrenous, in affected skin. CUA is an active vasculopathy characterized by patchy medial calcification of arterioles (0.6 mm diameter), and it afflicts patients with advanced CKD, especially those who receive warfarin. Clinical studies have demonstrated an association between calcitriol intake and CUA (62).

Vitamin D Analogs and Calcimimetics
Vitamin D receptor activators, such as paricalcitol and doxecalciferol, have been proposed as alternative therapeutic measures for secondary hyperparathyroidism in CKD to prevent the increased serum Ca x P that may contribute to increased vascular calcification. In studies of rats, Mizobuchi et al. (36) showed that, although calcitriol significantly increased the Ca x P and aortic calcium content, paricalcitol did not. Calcimimetics may have similar effects: By simulating serum calcium, they reduce PTH release from the parathyroid gland, which reduces the Ca x P product and vascular calcification (63,64). In a rat model of secondary hyperparathyroidism, cinacalcet did not produce vascular calcification (65).

	Conclusions

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
The relationships of vitamin D with atherosclerotic calcification and with aortic medial calcification are strong and most likely involve multiple mechanisms within the complex, bone-vascular-renal endocrine axis. In cell culture and in animal models, vitamin D treatment is clearly associated with increased vascular calcification; however, clinical studies show either no effect or an inverse relationship between vitamin D levels and vascular calcification, probably as a result of the complex, bone-vascular-renal-endocrine axis. Nevertheless, clinical studies also indicate that there is a narrow range of vitamin D levels within which vascular function is optimized, and levels above or below this range seem to confer increased risk for cardiovascular disease.

	Disclosures

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 
None.

	Footnotes

 
Published online ahead of print. Publication date available at www.cjasn.org.

	References

Top Abstract Introduction Cell and Organ Culture... Animal Models of Vascular... Clinical Studies of Vitamin... Conclusions Disclosures References

 

1. US Renal Data System: Causes of death. In: USRDS 1998 Annual Data Report, Bethesda, National Institute of Diabetes and Digestive and Kidney Diseases,1999 pp79 –90
2. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol9[Suppl] :S16 –S23,1998[CrossRef][Medline]
3. Eggen DA, Strong JP, McGill HC Jr: Coronary calcification: Relationship to clinically significant coronary lesions and race, sex, and topographic distribution. Circulation32 :948 –955,1965[Abstract/Free Full Text]
4. Iribarren C, Sidney S, Sternfeld B, Browner WS: Calcification of the aortic arch: Risk factors and association with coronary heart disease, stroke, and peripheral vascular disease. JAMA283 :2810 –2815,2000[Abstract/Free Full Text]
5. Keelan PC, Bielak LF, Ashai K, Jamjoum LS, Denktas AE, Rumberger JA, Sheedy IP, Peyser PA, Schwartz RS: Long-term prognostic value of coronary calcification detected by electron-beam computed tomography in patients undergoing coronary angiography. Circulation104 :412 –417,2001[Abstract/Free Full Text]
6. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med342 :1478 –1483,2000[Abstract/Free Full Text]
7. Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, Kuruoglu S, Arisoy N: Coronary artery calcifications in children with end-stage renal disease. Pediatr Nephrol21 :1426 –1433,2006[CrossRef][Medline]
8. Moe SM, Chen NX: Pathophysiology of vascular calcification in chronic kidney disease. Circ Res95 :560 –567,2004[Abstract/Free Full Text]
9. Wada T, McKee MD, Steitz S, Giachelli CM: Calcification of vascular smooth muscle cell cultures: Inhibition by osteopontin. Circ Res84 :166 –178,1999[Abstract/Free Full Text]
10. Jara A, Chacon C, Felsenfeld AJ: How dietary phosphate, renal failure and calcitriol administration affect the serum calcium-phosphate relationship in the rat. Nephrol Dial Transplant17 :765 –771,2002[Abstract/Free Full Text]
11. Norman PE, Powell JT: Vitamin D, shedding light on the development of disease in peripheral arteries. Arterioscler Thromb Vasc Biol25 :39 –46,2005[Abstract/Free Full Text]
12. Shao JS, Cai J, Towler DA: Molecular mechanisms of vascular calcification: Lessons learned from the aorta. Arterioscler Thromb Vasc Biol26 :1423 –1430,2006[Abstract/Free Full Text]
13. Abedin M, Tintut Y, Demer LL: Vascular calcification: Mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol24 :1161 –1170,2004[Abstract/Free Full Text]
14. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA: Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest115 :1210 –1220,2005[CrossRef][Medline]
15. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola SH, Rajamannan NM: Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol47 :1707 –1712,2006[Abstract/Free Full Text]
16. Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS: Bone formation and inflammation in cardiac valves. Circulation103 :1522 –1528,2001[Abstract/Free Full Text]
17. Qiao JH, Mertens RB, Fishbein MC, Geller SA: Cartilaginous metaplasia in calcified diabetic peripheral vascular disease: Morphologic evidence of enchondral ossification. Hum Pathol34 :402 –407,2003[CrossRef][Medline]
18. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest91 :1800 –1809,1993[Medline]
19. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest92 :1686 –1696,1993[Medline]
20. Proudfoot D, Skepper JN, Shanahan CM, Weissberg PL: Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol18 :379 –388,1998[Abstract/Free Full Text]
21. Tintut Y, Parhami F, Bostrom K, Jackson SM, Demer LL: cAMP stimulates osteoblast-like differentiation of calcifying vascular cells: Potential signaling pathway for vascular calcification. J Biol Chem273 :7547 –7553,1998[Abstract/Free Full Text]
22. Collett GD, Sage AP, Kirton JP, Alexander MY, Gilmore AP, Canfield AE: Axl/phosphatidylinositol 3-kinase signaling inhibits mineral deposition by vascular smooth muscle cells. Circ Res100 :502 –509,2007[Abstract/Free Full Text]
23. Jono S, Nishizawa Y, Shioi A, Morii H: 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation98 :1302 –1306,1998[Abstract/Free Full Text]
24. Shioi A, Katagi M, Okuno Y, Mori K, Jono S, Koyama H, Nishizawa Y: Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: Roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res91 :9 –16,2002[Abstract/Free Full Text]
25. Inoue T, Kawashima H: 1,25-Dihydroxyvitamin D3 stimulates 45Ca2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem Biophys Res Commun152 :1388 –1394,1988[CrossRef][Medline]
26. Lomashvili K, Garg P, O'Neill WC: Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int69 :1464 –1470,2006[Medline]
27. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res87 :214 –220,2000[Abstract/Free Full Text]
28. Xue H, McCarron DA, Bukoski RD: 1,25 (OH)2 vitamin D3 attenuates the loss of resistance artery contractile function associated with incubation in culture media. Biochem Biophys Res Commun174 :11 –17,1991[CrossRef][Medline]
29. Teramoto T, Endo K, Ikeda K, Kubodera N, Kinoshita M, Yamanaka M, Ogata E: Binding of vitamin D to low-density-lipoprotein (LDL) and LDL receptor-mediated pathway into cells. Biochem Biophys Res Commun215 :199 –204,1995[CrossRef][Medline]
30. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J: Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest91 :2552 –2555,1993[Medline]
31. Gottfried E, Rehli M, Hahn J, Holler E, Andreesen R, Kreutz M: Monocyte-derived cells express CYP27A1 and convert vitamin D3 into its active metabolite. Biochem Biophys Res Commun349 :209 –213,2006[CrossRef][Medline]
32. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL: Apoptosis regulates human vascular calcification in vitro: Evidence for initiation of vascular calcification by apoptotic bodies. Circ Res87 :1055 –1062,2000[Abstract/Free Full Text]
33. Hass GM, Landerholm W, Hemmens A: Production of calcific athero-arteriosclerosis and thromboarteritis with nicotine, vitamin D and dietary cholesterol. Am J Pathol49 :739 –771,1966[Medline]
34. Liu LB, Taylor CB, Peng SK, Mikkelson B: Experimental arteriosclerosis in Rhesus monkeys induced by multiple risk factors: cholesterol, vitamin D, and nicotine. Paroi Arterielle5 :25 –37,1979[Medline]
35. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM: Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res22 :860 –866,2007[CrossRef][Medline]
36. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int72 :709 –715,2007[CrossRef][Medline]
37. Price PA, Faus SA, Williamson MK: Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol20 :317 –327,2000[Abstract/Free Full Text]
38. Wu-Wong JR, Melnick J: Vascular calcification in chronic kidney failure: Role of vitamin D receptor. Curr Opin Investig Drugs8 :237 –247,2007[Medline]
39. Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol18 :1400 –1407,1998[Abstract/Free Full Text]
40. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature386 :78 –81,1997[CrossRef][Medline]
41. Bostrom K, Tsao D, Shen S, Wang Y, Demer LL: Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem276 :14044 –14052,2001[Abstract/Free Full Text]
42. Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U: Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens23 :1067 –1075,2005[Medline]
43. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature390 :45 –51,1997[CrossRef][Medline]
44. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest113 :561 –568,2004[CrossRef][Medline]
45. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD: Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol18 :2116 –2124,2007[Abstract/Free Full Text]
46. Ix JH, Chertow GM, Shlipak MG, Brandenburg VM, Ketteler M, Whooley MA: Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: Data from the Heart and Soul Study. Circulation115 :2533 –2539,2007[Abstract/Free Full Text]
47. Price PA, Williamson MK, Nguyen TM, Than TN: Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem279 :1594 –1600,2004[Abstract/Free Full Text]
48. Kondo T, Kitazawa R, Maeda S, Kitazawa S: 1 Alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res19 :1411 –1419,2004[CrossRef][Medline]
49. Orita Y, Yamamoto H, Kohno N, Sugihara M, Honda H, Kawamata S, Mito S, Soe NN, Yoshizumi M: Role of osteoprotegerin in arterial calcification: Development of new animal model. Arterioscler Thromb Vasc Biol27 :2058 –2064,2007[Abstract/Free Full Text]
50. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation117 :411 –420,2008[Abstract/Free Full Text]
51. Quelo I, Kahlen JP, Rascle A, Jurdic P, Carlberg C: Identification and characterization of a vitamin D3 response element of chicken carbonic anhydrase-II. DNA Cell Biol13 :1181 –1187,1994[Medline]
52. Ito M, Cho BH, Kummerow FA: Effects of a dietary magnesium deficiency and excess vitamin D3 on swine coronary arteries. J Am Coll Nutr9 :155 –163,1990[Abstract]
53. Watson KE, Abrolat ML, Malone LL, Hoeg JM, Doherty T, Detrano R, Demer LL: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation96 :1755 –1760,1997[Abstract/Free Full Text]
54. Doherty TM, Tang W, Dascalos S, Watson KE, Demer LL, Shavelle RM, Detrano RC: Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation96 :1477 –1481,1997[Abstract/Free Full Text]
55. London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol18 :613 –620,2007[Abstract/Free Full Text]
56. Arad Y, Spadaro LA, Roth M, Scordo J, Goodman K, Sherman S, Lerner G, Newstein D, Guerci AD: Serum concentration of calcium, 1,25 vitamin D and parathyroid hormone are not correlated with coronary calcifications: An electron beam computed tomography study. Coron Artery Dis9 :513 –518,1998[Medline]
57. Takeuchi A, Okano T, Ishida Y, Kobayashi T: Effects of dietary vitamin D intake on plasma levels of parathyroid hormone and vitamin D metabolites in healthy Japanese. Miner Electrolyte Metab21 :217 –222,1995[Medline]
58. Towler DA: Calciotropic hormones and arterial physiology: "D"-lightful insights. J Am Soc Nephrol18 :369 –373,2007[Free Full Text]
59. Milliner DS, Zinsmeister AR, Lieberman E, Landing B: Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int38 :931 –936,1990[Medline]
60. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M: Calcium/vitamin D supplementation and cardiovascular events. Circulation115 :846 –854,2007[Abstract/Free Full Text]
61. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB, Wolf M, Vasan RS: Vitamin D deficiency and risk of cardiovascular disease. Circulation117 :503 –511,2008[Abstract/Free Full Text]
62. Wilmer WA, Magro CM: Calciphylaxis: Emerging concepts in prevention, diagnosis, and treatment. Semin Dial15 :172 –186,2002[CrossRef][Medline]
63. Finch JL, Brown AJ, Slatopolsky E: Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol10 :980 –985,1999[Abstract/Free Full Text]
64. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med349 :446 –456,2003[Abstract/Free Full Text]
65. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D: 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant20 :1370 –1377,2005[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Johal and A. Levin Vitamin D and Parathyroid Hormone in General Populations: Understandings in 2009 and Applications to Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1508 - 1514. [Abstract] [Full Text] [PDF]

				J. N. Artaza, R. Mehrotra, and K. C. Norris Vitamin D and the Cardiovascular System Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1515 - 1522. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: CJN.01220308v1 3/5/1542    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsu, J. J. Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Hsu, J. J. Articles by Demer, L. L.